MENU
+Compare
IHE
ETF ticker: NYSE ARCA
AS OF
Feb 21, 04:59 PM (EDT)
Price
$71.53
Change
+$0.42 (+0.59%)
Net Assets
622.23M

IHE stock forecast, quote, news & analysis

Category: @Health
IHE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
A.I.Advisor
published price charts
Ad is loading...
A.I.Advisor
a Summary for IHE with price predictions
Feb 20, 2025

Aroon Indicator for IHE shows an upward move is likely

IHE's Aroon Indicator triggered a bullish signal on February 18, 2025. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 266 similar instances where the Aroon Indicator showed a similar pattern. In of the 266 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on January 15, 2025. You may want to consider a long position or call options on IHE as a result. In of 85 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for IHE just turned positive on February 20, 2025. Looking at past instances where IHE's MACD turned positive, the stock continued to rise in of 52 cases over the following month. The odds of a continued upward trend are .

IHE moved above its 50-day moving average on January 23, 2025 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for IHE crossed bullishly above the 50-day moving average on January 27, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where IHE advanced for three days, in of 309 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The 10-day RSI Indicator for IHE moved out of overbought territory on January 31, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 37 similar instances where the indicator moved out of overbought territory. In of the 37 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where IHE declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

IHE broke above its upper Bollinger Band on January 27, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Eli Lilly & Co (NYSE:LLY), Johnson & Johnson (NYSE:JNJ), Merck & Co (NYSE:MRK), Pfizer (NYSE:PFE), Bristol-Myers Squibb Co (NYSE:BMY), ZOETIS (NYSE:ZTS), Elanco Animal Health (NYSE:ELAN), Intra-Cellular Therapies (NASDAQ:ITCI).

Industry description

The investment seeks to track the investment results of the Dow Jones U.S. Select Pharmaceuticals Index. The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The underlying index measures the performance of the pharmaceuticals sector of the U.S. equity market. The underlying index includes pharmaceutical companies such as manufacturers of prescription or over-the-counter drugs or vaccines. The fund is non-diversified.

Market Cap

The average market capitalization across the iShares US Pharmaceuticals ETF ETF is 59.23B. The market cap for tickers in the group ranges from 122.68M to 739.66B. LLY holds the highest valuation in this group at 739.66B. The lowest valued company is SAVA at 122.68M.

High and low price notable news

The average weekly price growth across all stocks in the iShares US Pharmaceuticals ETF ETF was 8%. For the same ETF, the average monthly price growth was 35%, and the average quarterly price growth was 88%. SAVA experienced the highest price growth at 13%, while SUPN experienced the biggest fall at -12%.

Volume

The average weekly volume growth across all stocks in the iShares US Pharmaceuticals ETF ETF was -18%. For the same stocks of the ETF, the average monthly volume growth was -12% and the average quarterly volume growth was 52%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 53
P/E Growth Rating: 72
Price Growth Rating: 55
SMR Rating: 71
Profit Risk Rating: 71
Seasonality Score: -65 (-100 ... +100)
View a ticker or compare two or three
IHE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published General Information

General Information

Category Health

Profile
Fundamentals
Details
Category
Health
Address
iShares Trust400 Howard StreetSan Francisco
Phone
1-800-474-2737
Web
www.ishares.com